var data={"title":"Fluticasone (nasal): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Fluticasone (nasal): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7784?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=fluticasone-nasal-patient-drug-information\" class=\"drug drug_patient\">see &quot;Fluticasone (nasal): Patient drug information \t&quot;</a> and <a href=\"topic.htm?path=fluticasone-nasal-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Fluticasone (nasal): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349460\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Flonase Allergy Relief [OTC];</li>\n      <li>Flonase Sensimist [OTC];</li>\n      <li>Flonase [DSC];</li>\n      <li>GoodSense Nasoflow [OTC];</li>\n      <li>Ticaspray;</li>\n      <li>Veramyst [DSC];</li>\n      <li>Xhance</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349461\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Avamys;</li>\n      <li>Flonase</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349484\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Corticosteroid, Nasal</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349533\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Allergic rhinitis (fluticasone furoate): </b>Intranasal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Veramyst (Rx):</b> Initial: Two sprays (27.5 mcg/spray) per nostril once daily (110 mcg/day); once symptoms are controlled, may reduce dosage to 1 spray per nostril once daily (55 mcg/day) for maintenance therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Avamys (Rx) [Canadian product]:</b> Two sprays (27.5 mcg/spray) per nostril once daily (110 mcg/day). Total daily dosage should not exceed 2 sprays in each nostril (110 mcg/day).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nasal polyps (fluticasone propionate):</b> Intranasal: <b>Xhance (Rx):</b> One spray (93 mcg/spray) per nostril twice daily (372 mcg/day); some patients may require 2 sprays per nostril twice daily (744 mcg/day); maximum dose: 2 sprays per nostril twice daily (744 mcg/day).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nonallergic rhinitis (fluticasone propionate): </b>Intranasal: <b>Flonase (Rx): </b>Initial: Two sprays (50 mcg/spray) per nostril once daily (200 mcg/day); alternatively, the same total daily dosage may be divided and given as 1 spray per nostril twice daily (200 mcg/day). After the first few days, dosage may be reduced to 1 spray per nostril once daily for maintenance therapy (100 mcg/day) (maximum: 2 sprays in each nostril [200 mcg]/day).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Upper respiratory allergies (OTC):</b> Intranasal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b> ClariSpray, Flonase Allergy Relief, Good Sense Nasoflow</b> (fluticasone propionate): Initial: Two sprays (50 mcg/spray) per nostril once daily (200 mcg/day); after 1 week, may adjust to 1 or 2 sprays per nostril once daily (100 to 200 mcg/day). Do not use for more than 6 months unless instructed by health care provider.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Flonase Sensimist</b> (fluticasone furoate): Initial: Two sprays (27.5 mcg/spray) per nostril once daily (110 mcg/day); after 1 week, may adjust to 1 or 2 sprays per nostril once daily (55 to 110 mcg/day). Do not use for more than 6 months unless instructed by healthcare provider.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349532\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=fluticasone-nasal-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Fluticasone (nasal): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Allergic rhinitis (fluticasone furoate):</b>  Intranasal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Veramyst (Rx): </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 2 to 11 years: Initial: One spray (27.5 mcg/spray) per nostril once daily (55 mcg/day); patients not adequately responding may use 2 sprays per nostril once daily (110 mcg/day); once symptoms are controlled, dosage may be reduced to 1 spray per nostril once daily (55 mcg/day).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b> Avamys (Rx) [Canadian product]:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 2 to 11 years: Initial: One spray (27.5 mcg/spray) per nostril once daily (55 mcg/day); patients not adequately responding may use 2 sprays per nostril once daily (110 mcg/day); once symptoms are controlled, dosage should be reduced to 1 spray per nostril once daily (55 mcg/day). Total daily dosage should not exceed 2 sprays in each nostril (110 mcg/day).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Flonase (Rx) [Canadian product]:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 4 to 11 years: Usual dose: 1 to 2 sprays (50 mcg/spray) per nostril once daily; maximum dose: 2 sprays per nostril once daily (200 mcg/day). Once symptoms are controlled, reduce dose to 1 spray per nostril once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents 12 to 17 years: Usual dose: Two sprays (50 mcg/spray) per nostril once daily; patients with severe rhinitis may benefit from 2 sprays in each nostril twice daily; maximum dose: 400 mcg/day (4 sprays in each nostril).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nonallergic rhinitis: Flonase (Rx) (fluticasone propionate):</b> Intranasal: Children &ge;4 years and Adolescents: Initial: One spray (50 mcg/spray) per nostril once daily (100 mcg/day); may increase to 2 sprays per nostril once daily (200 mcg/day) if response not adequate; once symptoms are controlled, may reduce to 1 spray per nostril once daily (100 mcg/day) (maximum: 2 sprays in each nostril [200 mcg]/day). Dosing should be at regular intervals.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Upper respiratory allergies (OTC): </b>Intranasal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b> Flonase Sensimist</b> (fluticasone furoate):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 2 to 11 years: One spray (27.5 mcg/spray) per nostril once daily (55 mcg/day). Do not use for more than 2 months per year unless instructed by health care provider.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>ClariSpray, Flonase Allergy Relief, Good Sense Nasoflow</b> (fluticasone propionate):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 4 to 11 years: One spray (50 mcg/spray) per nostril once daily (100 mcg/day). Do not use for more than 2 months per year unless instructed by health care provider.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349534\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26337265\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xhance: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, dosage adjustment is likely not necessary. Following nasal administration, bioavailability and renal elimination are minimal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26337266\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use caution in moderate to severe impairment due to extensive hepatic metabolism.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242539\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Exhaler Suspension, Nasal, as propionate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Xhance: 93 mcg/actuation (16 mL) [contains benzalkonium chloride, edetate disodium dihydrate, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Nasal, as furoate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Flonase Sensimist: 27.5 mcg/spray (5.9 mL, 9.1 mL, 9.9 mL, 15.8 mL) [contains benzalkonium chloride, edetate disodium, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Veramyst: 27.5 mcg/spray (10 g [DSC]) [contains benzalkonium chloride]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Nasal, as propionate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Flonase: 50 mcg/actuation (16 g [DSC]) [contains benzalkonium chloride, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Flonase Allergy Relief: 50 mcg/actuation (9.9 mL, 15.8 mL, 18.2 mL) [contains benzalkonium chloride, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GoodSense Nasoflow: 50 mcg/actuation (15.8 mL) [contains alcohol, usp, benzalkonium chloride, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mcg/actuation (16 g, 9.9 mL, 15.8 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Therapy Pack, Nasal, as propionate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ticaspray: 50 mcg/actuation (1 ea) [contains benzalkonium chloride, polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349463\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21005929\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flonase 16 g bottles and Veramyst 10 g bottles contain 120 sprays each.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flonase Allergy Relief 9.9 mL bottles contain 60 sprays, and the 15.8 mL bottles contain 120 sprays.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349542\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suspension, Nasal, as furoate:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Avamys: 27.5 mcg/inhalation (4.5 g) [30 metered actuations; contains benzalkonium chloride]; (10 g) [120 metered actuations; contains benzalkonium chloride]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suspension, Nasal, as propionate:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Flonase: 50 mcg/actuation (16 g) [120 metered actuations; contains benzalkonium chloride, polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50617005\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Xhance (fluticasone propionate) nasal spray: FDA approved September 2017; availability anticipated in the second quarter of 2018.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242541\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">For intranasal use only; do not spray in eyes or mouth. Administer at regular intervals. Shake bottle gently before each use. Blow nose to clear nostrils. Insert applicator into nostril, keeping bottle upright, and close off the other nostril. Breathe in through nose. While inhaling, press pump to release spray. Discard after labeled number of doses has been used, even if bottle is not completely empty.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flonase: Prime pump (press 6 times until fine spray appears) prior to first use or if spray unused for &ge;7 days. Once weekly, nasal applicator may be removed and rinsed with warm water to clean.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Veramyst, Avamys [Canadian product]: Prime pump (press 6 times until fine spray appears) prior to first use, if spray unused for &ge;30 days, or if cap left off bottle for &ge;5 days. After each use, nozzle should be wiped with a clean, dry tissue. Once weekly, inside of cap should be cleaned with a clean, dry tissue.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flonase Sensimist: Shake bottle vigorously before using. Prime pump. Sniff gently after each spray. Wipe spray nozzle after each use with clean, dry tissue and replace cap.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xhance: Avoid spraying directly on the septum. Prior to first use, prime pump by gently shaking and press bottle 7 times until fine mist appears; if not used for &ge;7 days, re-prime pump again by shaking and releasing 2 sprays into the air. Insert nosepiece deep into one nostril and form a tight seal and then place the flexible mouthpiece into the mouth; blow into the mouthpiece, and while continuing to blow, push the bottle up to actuate the spray pump; continue to blow through the mouth, but do not inhale or exhale through the nose at the time of actuation; repeat in the other nostril for a full dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242540\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rx products:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Allergic rhinitis (Veramyst, Avamys [Canadian product], Flonase [Canadian product]):</b> Management of seasonal and perennial allergic rhinitis in adults and children &ge;2 years of age (Veramyst, Avamys) and in patients 4 to 17 years of age (Flonase)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Nasal polyps (Xhance):</b> Treatment of nasal polyps in patients &ge;18 years of age</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Nonallergic rhinitis (Flonase):</b> Management of the nasal symptoms of perennial nonallergic rhinitis in adults and pediatric patients &ge;4 years of age</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>OTC products:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Upper respiratory allergies:</b> Relief of hay fever or other upper respiratory allergies (eg, itchy and watery eyes, nasal congestion, runny nose, sneezing, itchy nose) in adults and children &ge;4 years of age (Clarispray, Flonase Allergy Relief, Good Sense Nasoflow) or children &ge;2 years of age (Flonase Sensimist)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25474743\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Acute bacterial rhinosinusitis, adjunct to antibiotics (empiric treatment); Chronic rhinosinusitis; Viral rhinosinusitis symptomatic relief</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349456\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Flonase may be confused with Flovent</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Allegro: Brand name for fluticasone [Israel], but also the brand name for frovatriptan [Germany] </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Allegro [Israel] may be confused with Allegra and Allegra-D brand names for fexofenadine and fexofenadine/pseudoephedrine, respectively, [US, Canada, and multiple international markets]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242531\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Central nervous system: Headache (4% to 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Body pain (1% to 3%), dizziness (1% to 3%), generalized ache (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight gain (1% to &lt;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea and vomiting (3% to 5%), abdominal pain (1% to 3%), diarrhea (1% to 3%), abdominal distress (1% to &lt;3%), toothache (1% to &lt;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Local irritation (nose: 4% to 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Increased intraocular pressure (1% to &lt;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Epistaxis (6% to 12%), nasal mucosa ulcer (3% to 8%; includes nasal septal ulceration), pharyngitis (3% to 8%), nasopharyngitis (8%), acute asthma (7%), nasal congestion (6%), acute sinusitis (5%), cough (4%), blood in nasal mucosa (1% to 3%), bronchitis (1% to 3%), flu-like symptoms (1% to 3%), rhinorrhea (1% to 3%), dry nose (1% to &lt;3%), oropharyngeal pain (1% to &lt;3%), sinusitis (1% to &lt;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Altered sense of smell, anaphylactoid reaction, anaphylaxis, angioedema, blurred vision, bronchospasm, cataract, conjunctivitis, contact dermatitis, dry eye syndrome, dry throat, dysgeusia, dyspnea, esophageal candidiasis, eye irritation, facial edema, glaucoma, growth suppression, hoarseness, hypersensitivity reaction, intestinal candidiasis, nasal candidiasis, nasal septum perforation, pharyngeal candidiasis, pruritus, skin rash, sore throat, throat irritation, tongue edema, urticaria, voice disorder, wheezing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242544\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to fluticasone or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OTC labeling: When used for self-medication, do not use in children &lt;4 years of age (Clarispray, Flonase Allergy Relief, Good Sense Nasoflow) or children &lt;2 years of age (Flonase Sensimist), for the treatment of asthma, or with current injury or surgery to nose that is not fully healed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for intranasal steroids is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Flonase: Untreated fungal, bacterial, or tuberculosis infections of the respiratory tract</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242529\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Pediatric patients may be more susceptible to systemic toxicity. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Patients receiving &ge;20 mg per day of prednisone (or equivalent) may be most susceptible. Concurrent use of ritonavir (and potentially other strong inhibitors of CYP3A4) may increase fluticasone levels and effects on HPA suppression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Delayed wound healing: Avoid use in patients with recent nasal septal ulcers, nasal surgery, or nasal trauma until healing has occurred.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions (including anaphylaxis, angioedema, rash, contact dermatitis, hypotension, bronchospasm, and urticaria) have been reported; discontinue for severe reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunosuppression: Prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Exposure to chickenpox and/or measles should be avoided, especially if not immunized; if the patient is exposed, prophylaxis with varicella zoster immune globulin or pooled intramuscular immunoglobulin, respectively, may be indicated; if chickenpox develops, treatment with antiviral agents may be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Local nasal effects: Nasal septal perforation, nasal ulceration, nasal erosion, epistaxis, and localized <i>Candida albicans</i> infections of the nose and/or pharynx may occur. Monitor patients periodically for adverse nasal effects; discontinuation of therapy may be necessary if an infection occurs; discontinue therapy if nasal septal perforation occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with moderate to severe hepatic impairment (accumulation may occur); monitor patients closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infections: Use caution or avoid use in patients with active or quiescent tuberculosis infections of the respiratory tract, systemic fungal, bacterial, viral, or parasitic infections, or ocular herpes simplex. Do not use in untreated localized infection involving the nasal mucosa; concurrent antimicrobial therapy should be administered if bacterial infection of the sinuses is suspected/confirmed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use. Consider routine eye exams in long-term users or in patients who report visual changes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatrics: Avoid using higher than recommended dosages; suppression of linear growth (ie, reduction of growth velocity), reduced bone mineral density, or hypercortisolism (Cushing syndrome) may occur; titrate to lowest effective dose. Reduction in growth velocity may occur when corticosteroids are administered to pediatric patients, even at recommended doses via intranasal route (monitor growth). Use for the shortest amount of time necessary to achieve symptom relief.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Prior to use, the dose and duration of treatment should be based on the risk vs benefit for each individual patient. In general, use the smallest effective dose for the shortest duration of time to minimize adverse events. There have been reports of systemic corticosteroid withdrawal symptoms (eg, joint/muscle pain, lassitude, depression) when withdrawing inhalation therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Self-medication (OTC use): Consult a health care provider before use if you taking medicine for HIV infection (eg, ritonavir), steroid for asthma, allergies, or skin rash, or ketoconazole (for a fungal infection). Discontinue use and consult a health care provider if you have come in contact with someone who has chicken pox, measles, or tuberculosis, symptoms do not get better within 7 days or new symptoms occur (eg, severe facial pain, thick nasal discharge), constant whistling sound from nose, changes in vision, or severe or frequent nosebleeds. Stinging or sneezing may occur for a few seconds after use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal: Symptoms of corticosteroid withdrawal (eg, joint pain, muscle pain, lassitude, depression) may occur when transferring from a systemic corticosteroid to a topical corticosteroid.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349495\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242533\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9135&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Fluticasone (Nasal).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Corticosteroids (Nasal) may enhance the hyponatremic effect of Desmopressin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242534\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349487\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies. Fluticasone can be detected in cord blood following maternal use via oral inhalation during pregnancy; one woman in the study was also using intranasal fluticasone (Battista 2016). Hypoadrenalism may occur in newborns following maternal use of corticosteroids in pregnancy; monitor.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Intranasal corticosteroids, including fluticasone, may be acceptable for the treatment of rhinitis during pregnancy when used at recommended doses (Lal 2016; Wallace 2008). Pregnant females adequately controlled on fluticasone may continue therapy; if initiating treatment during pregnancy, use of an agent with more data during pregnancy may be preferred (Namazy 2016; Wallace 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9771508\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if sufficient quantities of fluticasone are absorbed following inhalation to produce detectable amounts in breast milk. Systemic corticosteroids are present in human milk. The manufacturer recommends caution be used if administered to breastfeeding females.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242537\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Growth (adolescents and children); signs/symptoms of HPA axis suppression/adrenal insufficiency; possible eosinophilic conditions (including eosinophilic granulomatosis with polyangiitis [formerly known as Churg-Strauss]); ocular changes; signs/symptoms of <i>Candida</i> infection (long-term therapy); hepatic function</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242527\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Fluticasone belongs to a group of corticosteroids which utilizes a fluorocarbothioate ester linkage at the 17 carbon position; extremely potent vasoconstrictive and anti-inflammatory activity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242543\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Maximal benefit may take several days or several months (Xhance)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Fluticasone propionate: 4.2 L/kg; Fluticasone furoate: V<sub>d,ss</sub>: 608 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 99%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via CYP3A4 to 17 beta-carboxylic acid (negligible activity)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: &lt;2%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: IV: Fluticasone propionate: ~8 hours (~7.8 hours [Xhance]); Fluticasone furoate: ~15 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Oral: Feces (as parent drug and metabolites); Urine (&lt;5% as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349541\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Exhaler Suspension</b> (Xhance Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">93 mcg/ACT (16 mL): $510.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Flonase Allergy Relief Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mcg/ACT (9.9 mL): $14.21</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Flonase Sensimist Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">27.5 mcg/spray (15.8 mL): $26.86</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Fluticasone Propionate Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mcg/ACT (16 g): $84.32</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Therapy Pack</b> (Ticaspray Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50MCG/ACT 0.9% (1): $3,783.22</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961908\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Alenys (AR);</li>\n      <li>Alisade (EE, MT);</li>\n      <li>Allegro (IL);</li>\n      <li>Allermist (JP);</li>\n      <li>Avamys (AE, AT, AU, BE, BH, BR, CH, CL, CO, CR, CY, CZ, DE, DK, DO, EC, EE, ES, ET, FR, GB, GR, GT, HK, HN, HR, ID, IE, IL, IS, IT, JO, KR, KW, LB, LK, LT, LU, LV, MT, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, QA, RO, SA, SE, SG, SI, SK, SV, TH, TR, TW, UY, VN, ZW);</li>\n      <li>Avaspray (BD);</li>\n      <li>Clefan (MY);</li>\n      <li>Dalmam AQ (HK);</li>\n      <li>Flixonas (PK);</li>\n      <li>Flixonase (AR, AT, AU, BE, BG, BH, BR, CL, CN, CY, CZ, DK, DO, EC, EE, EG, ES, FI, FR, GB, HK, HN, HR, IE, IL, IS, IT, JM, JO, KR, KW, LB, LK, LT, LU, LV, MT, NL, NZ, PA, PE, PH, PL, PY, QA, RO, RU, SA, SG, SI, SK, SV, TH, TR, TT, TW, UY, VE, VN);</li>\n      <li>Flixonase Nasule (IL);</li>\n      <li>Flomist (MY, ZW);</li>\n      <li>Flusort (PH);</li>\n      <li>Flutaide (PT);</li>\n      <li>Flutica (BD, DE);</li>\n      <li>Fluticone (LK);</li>\n      <li>Flutide (NO, SE);</li>\n      <li>Flutinasal (GR);</li>\n      <li>Flutinase (CH);</li>\n      <li>Flutinide (MY);</li>\n      <li>Flutitrim (SG);</li>\n      <li>Lutisone (HK);</li>\n      <li>Nasofan (HK);</li>\n      <li>Nasoflo (PH);</li>\n      <li>Novex (CO);</li>\n      <li>Perinase (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Avamys (fluticasone) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; August 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Battista MC, Boutin M, Venne P, et al. Maternal inhaled fluticasone propionate intake during pregnancy is detected in neonatal cord blood. <i>Bioanalysis</i>. 2016 Jun 28. [Epub ahead of print]<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluticasone-nasal-drug-information/abstract-text/27349687/pubmed\" target=\"_blank\" id=\"27349687\">27349687</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chow AW, Benninger MS, Brook I, et al, &ldquo;IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults,&rdquo; <i>Clin Infect Dis</i>, 2012, 54(8):e72-112.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluticasone-nasal-drug-information/abstract-text/22438350/pubmed\" target=\"_blank\" id=\"22438350\">22438350</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ClariSpray (fluticasone propionate) [prescribing information]. Morristown, NJ: Bayer; May 2016.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluticasone-nasal-drug-information/abstract-text/22438350/pubmed\" target=\"_blank\" id=\"22438350\">22438350</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flonase (fluticasone) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; July 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flonase Allergy Relief (fluticasone) [prescribing information]. Warren, NJ: GSK Consumer Healthcare; received January 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flonase (fluticasone) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flonase Sensimist (fluticasone) [prescribing information]. Warren, NJ; GlaxoSmithKline; July 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Good Sense Nasoflow (fluticasone propionate) [prescribing information]. Allegan, MI: L. Perrigo Co; June 2016.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluticasone-nasal-drug-information/abstract-text/22438350/pubmed\" target=\"_blank\" id=\"22438350\">22438350</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lal D, Jategaonkar AA, Borish L, et al. Management of rhinosinusitis during pregnancy: systematic review and expert panel recommendations. <i>Rhinology</i>. 2016;54(2):99-104.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluticasone-nasal-drug-information/abstract-text/26800862/pubmed\" target=\"_blank\" id=\"26800862\">26800862</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Namazy J, Schatz M. The treatment of allergic respiratory disease during pregnancy. <i>J Investig Allergol Clin Immunol</i>. 2016;26(1):1-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluticasone-nasal-drug-information/abstract-text/27012010/pubmed\" target=\"_blank\" id=\"27012010\">27012010</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25832968\"></a>Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. <i>Otolaryngol Head Neck Surg</i>. 2015;152(2 Suppl):S1-S39.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluticasone-nasal-drug-information/abstract-text/25832968/pubmed\" target=\"_blank\" id=\"25832968\">25832968</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Veramyst (fluticasone) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; July 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wallace DV, Dykewicz MS, Bernstein DI, et al, &quot;The Diagnosis and Management of Rhinitis: An Updated Practice Parameter,&quot; <i>J Allergy Clin Immunol</i>, 2008, 122(2 Suppl):S1-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluticasone-nasal-drug-information/abstract-text/18662584/pubmed\" target=\"_blank\" id=\"18662584\">18662584</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Xhance (fluticasone propionate) [prescribing information]. Yardley, PA: OptiNose US Inc; September 2017.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9135 Version 194.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F9349460\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F9349461\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F9349484\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F9349533\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F9349532\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F9349534\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F26337265\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F26337266\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F242539\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F9349463\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F21005929\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F9349542\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F50617005\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F242541\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F242540\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25474743\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F9349456\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F242531\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F242544\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F242529\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F9349495\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F242533\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F242534\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F9349487\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F9771508\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F242537\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F242527\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F242543\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F9349541\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961908\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9135|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=fluticasone-nasal-patient-drug-information\" class=\"drug drug_patient\">Fluticasone (nasal): Patient drug information \t</a></li><li><a href=\"topic.htm?path=fluticasone-nasal-pediatric-drug-information\" class=\"drug drug_pediatric\">Fluticasone (nasal): Pediatric drug information</a></li></ul></div></div>","javascript":null}